 Timothy Benke
Concepts (537)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rett Syndrome | 29 | 2025 | 40 | 7.390 |
Why?
| | Spasms, Infantile | 34 | 2024 | 123 | 7.000 |
Why?
| | Epileptic Syndromes | 32 | 2024 | 84 | 6.240 |
Why?
| | Seizures | 20 | 2025 | 426 | 3.910 |
Why?
| | Epilepsy | 14 | 2025 | 333 | 2.970 |
Why?
| | Methyl-CpG-Binding Protein 2 | 10 | 2025 | 21 | 2.770 |
Why?
| | Receptors, AMPA | 14 | 2024 | 141 | 2.280 |
Why?
| | Hippocampus | 23 | 2025 | 895 | 2.140 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 14 | 2025 | 219 | 2.100 |
Why?
| | Long-Term Synaptic Depression | 4 | 2025 | 56 | 1.750 |
Why?
| | Receptors, Metabotropic Glutamate | 3 | 2025 | 40 | 1.730 |
Why?
| | Long-Term Potentiation | 10 | 2024 | 198 | 1.730 |
Why?
| | Vision Disorders | 8 | 2023 | 142 | 1.480 |
Why?
| | Clinical Trials as Topic | 5 | 2024 | 1050 | 1.320 |
Why?
| | Synapses | 14 | 2024 | 427 | 1.260 |
Why?
| | Movement Disorders | 5 | 2023 | 58 | 1.260 |
Why?
| | Calcium Channels, L-Type | 4 | 2025 | 118 | 1.160 |
Why?
| | Excitatory Postsynaptic Potentials | 12 | 2024 | 124 | 1.150 |
Why?
| | Psychometrics | 11 | 2024 | 720 | 1.130 |
Why?
| | Cognition Disorders | 9 | 2020 | 496 | 1.110 |
Why?
| | Protein Phosphatase 2 | 2 | 2025 | 41 | 1.010 |
Why?
| | Neurodevelopmental Disorders | 4 | 2024 | 181 | 0.960 |
Why?
| | Loss of Function Mutation | 1 | 2025 | 46 | 0.940 |
Why?
| | Genetic Testing | 3 | 2025 | 460 | 0.930 |
Why?
| | CA1 Region, Hippocampal | 4 | 2024 | 52 | 0.900 |
Why?
| | Anticonvulsants | 6 | 2023 | 217 | 0.890 |
Why?
| | Rats, Sprague-Dawley | 14 | 2025 | 2486 | 0.890 |
Why?
| | Neuropsychological Tests | 16 | 2020 | 1023 | 0.860 |
Why?
| | Internationality | 1 | 2024 | 155 | 0.860 |
Why?
| | Kainic Acid | 10 | 2024 | 35 | 0.850 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2020 | 15 | 0.840 |
Why?
| | Brain Ischemia | 3 | 2021 | 338 | 0.830 |
Why?
| | Social Behavior | 3 | 2015 | 287 | 0.800 |
Why?
| | Autistic Disorder | 3 | 2022 | 204 | 0.790 |
Why?
| | Severity of Illness Index | 11 | 2024 | 2828 | 0.770 |
Why?
| | Disease Models, Animal | 12 | 2025 | 4295 | 0.730 |
Why?
| | Infarction, Posterior Cerebral Artery | 1 | 2021 | 3 | 0.730 |
Why?
| | Memory Disorders | 4 | 2014 | 164 | 0.710 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2024 | 539 | 0.710 |
Why?
| | Rats | 22 | 2025 | 5647 | 0.700 |
Why?
| | Child | 47 | 2025 | 21935 | 0.650 |
Why?
| | Developmental Disabilities | 2 | 2019 | 263 | 0.630 |
Why?
| | Humans | 111 | 2025 | 137585 | 0.630 |
Why?
| | Child, Preschool | 31 | 2025 | 11074 | 0.630 |
Why?
| | Genetic Therapy | 1 | 2021 | 297 | 0.630 |
Why?
| | Electroencephalography | 14 | 2025 | 423 | 0.620 |
Why?
| | Caregivers | 7 | 2025 | 877 | 0.610 |
Why?
| | Maze Learning | 3 | 2014 | 103 | 0.590 |
Why?
| | Symptom Assessment | 1 | 2019 | 128 | 0.560 |
Why?
| | Phenotype | 13 | 2025 | 3196 | 0.560 |
Why?
| | Animals | 43 | 2025 | 36940 | 0.550 |
Why?
| | Neuronal Plasticity | 3 | 2018 | 290 | 0.550 |
Why?
| | Stroke | 2 | 2021 | 1120 | 0.540 |
Why?
| | Schizophrenia | 1 | 2021 | 439 | 0.540 |
Why?
| | Male | 68 | 2025 | 67762 | 0.540 |
Why?
| | Cerebral Cortex | 7 | 2021 | 433 | 0.530 |
Why?
| | Quality of Life | 9 | 2025 | 2892 | 0.530 |
Why?
| | Animals, Newborn | 11 | 2024 | 844 | 0.520 |
Why?
| | Speech Disorders | 3 | 2019 | 31 | 0.500 |
Why?
| | Female | 70 | 2025 | 73304 | 0.500 |
Why?
| | Genomics | 1 | 2021 | 795 | 0.500 |
Why?
| | Hair Cells, Vestibular | 4 | 2023 | 29 | 0.480 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 5 | 2024 | 188 | 0.440 |
Why?
| | Dementia | 5 | 2007 | 259 | 0.440 |
Why?
| | Surveys and Questionnaires | 11 | 2025 | 5778 | 0.440 |
Why?
| | Reproducibility of Results | 11 | 2024 | 3284 | 0.430 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2023 | 143 | 0.420 |
Why?
| | Infant | 20 | 2025 | 9465 | 0.410 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2013 | 50 | 0.400 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1774 | 0.390 |
Why?
| | Adolescent | 33 | 2025 | 21513 | 0.370 |
Why?
| | Behavior, Animal | 1 | 2015 | 501 | 0.360 |
Why?
| | Mutation | 14 | 2025 | 3958 | 0.360 |
Why?
| | Nervous System Diseases | 2 | 2023 | 266 | 0.340 |
Why?
| | Glutamic Acid | 4 | 2007 | 246 | 0.330 |
Why?
| | Ion Channels | 4 | 2012 | 133 | 0.330 |
Why?
| | Chromosome Duplication | 2 | 2020 | 5 | 0.330 |
Why?
| | Adult | 36 | 2025 | 37929 | 0.310 |
Why?
| | Communication | 3 | 2024 | 879 | 0.310 |
Why?
| | Basal Ganglia Diseases | 2 | 2009 | 8 | 0.300 |
Why?
| | Excitatory Amino Acid Agonists | 4 | 2015 | 39 | 0.300 |
Why?
| | Parents | 4 | 2024 | 1347 | 0.300 |
Why?
| | Treatment Outcome | 12 | 2025 | 10811 | 0.290 |
Why?
| | Genetic Association Studies | 2 | 2020 | 377 | 0.280 |
Why?
| | Young Adult | 18 | 2025 | 13209 | 0.280 |
Why?
| | Space Perception | 1 | 2008 | 80 | 0.280 |
Why?
| | Alzheimer Disease | 2 | 2020 | 560 | 0.280 |
Why?
| | Risk-Taking | 2 | 2009 | 348 | 0.270 |
Why?
| | Evoked Potentials, Visual | 3 | 2023 | 35 | 0.270 |
Why?
| | Interneurons | 2 | 2025 | 122 | 0.270 |
Why?
| | Dystonia | 1 | 2007 | 25 | 0.270 |
Why?
| | Memory, Short-Term | 2 | 2008 | 250 | 0.260 |
Why?
| | Models, Neurological | 6 | 2005 | 242 | 0.260 |
Why?
| | Membrane Potentials | 6 | 2023 | 284 | 0.260 |
Why?
| | Brain Abscess | 1 | 2006 | 10 | 0.250 |
Why?
| | Calcium | 6 | 2023 | 1199 | 0.250 |
Why?
| | Exons | 2 | 2024 | 355 | 0.250 |
Why?
| | Parkinson Disease | 6 | 2011 | 493 | 0.250 |
Why?
| | Amnesia | 2 | 2005 | 43 | 0.250 |
Why?
| | Neurons | 7 | 2023 | 1590 | 0.250 |
Why?
| | Indans | 1 | 2005 | 11 | 0.240 |
Why?
| | Prosencephalon | 1 | 2005 | 48 | 0.240 |
Why?
| | Cholinesterase Inhibitors | 1 | 2005 | 30 | 0.240 |
Why?
| | Gamma Rhythm | 1 | 2025 | 6 | 0.240 |
Why?
| | Pregnanolone | 2 | 2024 | 37 | 0.240 |
Why?
| | Aneurysm, Ruptured | 1 | 2005 | 35 | 0.240 |
Why?
| | Amnesia, Transient Global | 1 | 2005 | 1 | 0.240 |
Why?
| | Amobarbital | 1 | 2005 | 2 | 0.240 |
Why?
| | Age Factors | 5 | 2020 | 3295 | 0.240 |
Why?
| | Hydrocephalus | 2 | 2024 | 106 | 0.230 |
Why?
| | Evoked Potentials | 3 | 2023 | 123 | 0.230 |
Why?
| | Tissue Culture Techniques | 2 | 2015 | 78 | 0.230 |
Why?
| | Long QT Syndrome | 2 | 2022 | 70 | 0.230 |
Why?
| | Genetic Diseases, X-Linked | 2 | 2024 | 24 | 0.230 |
Why?
| | Delayed Diagnosis | 1 | 2025 | 91 | 0.230 |
Why?
| | Double-Blind Method | 7 | 2025 | 1993 | 0.230 |
Why?
| | Forkhead Transcription Factors | 1 | 2025 | 191 | 0.220 |
Why?
| | Brain Diseases | 3 | 2023 | 141 | 0.220 |
Why?
| | Signal Transduction | 3 | 2024 | 5079 | 0.220 |
Why?
| | Twins, Monozygotic | 1 | 2025 | 203 | 0.220 |
Why?
| | Pyramidal Cells | 4 | 2024 | 74 | 0.220 |
Why?
| | Frameshift Mutation | 1 | 2024 | 32 | 0.220 |
Why?
| | Endpoint Determination | 1 | 2024 | 77 | 0.220 |
Why?
| | 5' Untranslated Regions | 1 | 2024 | 58 | 0.220 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2025 | 136 | 0.220 |
Why?
| | Patch-Clamp Techniques | 8 | 2015 | 286 | 0.220 |
Why?
| | Tetanus Toxin | 1 | 2004 | 6 | 0.220 |
Why?
| | Thalamus | 2 | 2021 | 107 | 0.220 |
Why?
| | Mosaicism | 1 | 2024 | 73 | 0.220 |
Why?
| | Bias | 1 | 2025 | 218 | 0.210 |
Why?
| | Ketamine | 1 | 2025 | 94 | 0.210 |
Why?
| | Brain | 11 | 2024 | 2668 | 0.210 |
Why?
| | Neurodegenerative Diseases | 1 | 2006 | 135 | 0.210 |
Why?
| | Piperidines | 1 | 2005 | 206 | 0.210 |
Why?
| | Nerve Tissue Proteins | 3 | 2025 | 596 | 0.210 |
Why?
| | Celiac Disease | 1 | 2007 | 294 | 0.210 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2024 | 51 | 0.210 |
Why?
| | Parvalbumins | 1 | 2023 | 25 | 0.210 |
Why?
| | Glycine | 1 | 2024 | 176 | 0.200 |
Why?
| | Cerebral Aqueduct | 1 | 2003 | 4 | 0.200 |
Why?
| | Olfactory Bulb | 1 | 2024 | 93 | 0.200 |
Why?
| | Decision Making | 2 | 2009 | 900 | 0.200 |
Why?
| | Congresses as Topic | 1 | 2024 | 233 | 0.200 |
Why?
| | Ventriculostomy | 1 | 2003 | 21 | 0.200 |
Why?
| | Status Epilepticus | 1 | 2023 | 50 | 0.200 |
Why?
| | Chromosomes, Human, X | 2 | 2023 | 73 | 0.200 |
Why?
| | Dendrites | 3 | 2007 | 105 | 0.200 |
Why?
| | Hypnotics and Sedatives | 1 | 2005 | 200 | 0.200 |
Why?
| | Learning | 1 | 2007 | 409 | 0.200 |
Why?
| | Vestibule, Labyrinth | 1 | 2023 | 65 | 0.190 |
Why?
| | Calcinosis | 1 | 2004 | 235 | 0.190 |
Why?
| | Child Behavior | 2 | 2024 | 248 | 0.190 |
Why?
| | Sleep Wake Disorders | 2 | 2024 | 286 | 0.190 |
Why?
| | Checklist | 1 | 2023 | 93 | 0.190 |
Why?
| | Disorders of Excessive Somnolence | 1 | 2022 | 32 | 0.190 |
Why?
| | Anti-Anxiety Agents | 1 | 2022 | 46 | 0.190 |
Why?
| | Posterior Cerebral Artery | 1 | 2021 | 7 | 0.180 |
Why?
| | Ultrasonics | 1 | 2021 | 49 | 0.180 |
Why?
| | Phosphorylation | 3 | 2015 | 1759 | 0.180 |
Why?
| | Consensus | 1 | 2024 | 683 | 0.180 |
Why?
| | Acute Disease | 4 | 2015 | 1007 | 0.180 |
Why?
| | Neurologists | 1 | 2021 | 21 | 0.180 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 24 | 0.180 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 142 | 0.180 |
Why?
| | Vision, Ocular | 1 | 2021 | 37 | 0.180 |
Why?
| | Synaptic Transmission | 4 | 2023 | 289 | 0.180 |
Why?
| | Corpus Callosum | 2 | 2019 | 71 | 0.180 |
Why?
| | Visual Pathways | 1 | 2021 | 55 | 0.170 |
Why?
| | Memory | 3 | 2008 | 248 | 0.170 |
Why?
| | Subcellular Fractions | 2 | 2013 | 82 | 0.170 |
Why?
| | In Vitro Techniques | 6 | 2013 | 1092 | 0.170 |
Why?
| | Athletic Injuries | 1 | 2007 | 529 | 0.170 |
Why?
| | Intellectual Disability | 1 | 2022 | 165 | 0.170 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2019 | 36 | 0.170 |
Why?
| | Endoscopy | 1 | 2003 | 318 | 0.160 |
Why?
| | Epilepsy, Temporal Lobe | 3 | 2005 | 38 | 0.160 |
Why?
| | Electrophysiology | 5 | 2007 | 217 | 0.160 |
Why?
| | Disease Progression | 3 | 2024 | 2757 | 0.160 |
Why?
| | Cyclins | 1 | 2020 | 91 | 0.160 |
Why?
| | Analysis of Variance | 5 | 2009 | 1316 | 0.160 |
Why?
| | Autism Spectrum Disorder | 2 | 2022 | 395 | 0.160 |
Why?
| | Follow-Up Studies | 8 | 2021 | 5131 | 0.160 |
Why?
| | Blotting, Western | 2 | 2015 | 1226 | 0.160 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 165 | 0.160 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2031 | 0.160 |
Why?
| | Action Potentials | 6 | 2023 | 493 | 0.150 |
Why?
| | Pediatrics | 1 | 2007 | 1101 | 0.150 |
Why?
| | Mutation, Missense | 4 | 2024 | 341 | 0.150 |
Why?
| | Gene Duplication | 1 | 2019 | 68 | 0.150 |
Why?
| | Mice | 9 | 2025 | 17787 | 0.150 |
Why?
| | Vagus Nerve Stimulation | 1 | 2019 | 29 | 0.150 |
Why?
| | Diet, Ketogenic | 1 | 2019 | 37 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 10 | 2010 | 3566 | 0.150 |
Why?
| | Glutamates | 3 | 2023 | 59 | 0.150 |
Why?
| | Face | 1 | 2020 | 173 | 0.150 |
Why?
| | Syndrome | 3 | 2020 | 358 | 0.150 |
Why?
| | Motor Activity | 2 | 2020 | 718 | 0.150 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5757 | 0.150 |
Why?
| | Judgment | 1 | 2018 | 60 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.140 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 76 | 0.140 |
Why?
| | Aphasia | 3 | 2004 | 21 | 0.140 |
Why?
| | Delphi Technique | 1 | 2019 | 280 | 0.140 |
Why?
| | Syncope, Vasovagal | 1 | 1997 | 6 | 0.130 |
Why?
| | Delusions | 1 | 1997 | 10 | 0.130 |
Why?
| | Alternative Splicing | 1 | 2019 | 229 | 0.130 |
Why?
| | Epilepsy, Generalized | 1 | 1997 | 19 | 0.130 |
Why?
| | Memantine | 2 | 2012 | 14 | 0.130 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 209 | 0.130 |
Why?
| | Epilepsies, Partial | 1 | 1997 | 50 | 0.130 |
Why?
| | Genetic Variation | 1 | 2021 | 991 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 580 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 934 | 0.120 |
Why?
| | Time | 1 | 2015 | 83 | 0.120 |
Why?
| | Physicians | 1 | 2024 | 910 | 0.120 |
Why?
| | Brain Damage, Chronic | 1 | 1995 | 18 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 322 | 0.120 |
Why?
| | Time Factors | 9 | 2009 | 6828 | 0.120 |
Why?
| | Sex Factors | 2 | 2019 | 2071 | 0.110 |
Why?
| | Organ Culture Techniques | 2 | 2016 | 156 | 0.110 |
Why?
| | Precision Medicine | 1 | 2019 | 429 | 0.110 |
Why?
| | Middle Aged | 16 | 2024 | 33479 | 0.110 |
Why?
| | N-Methylaspartate | 2 | 1996 | 40 | 0.110 |
Why?
| | Meningitis, Bacterial | 1 | 1995 | 47 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2025 | 15657 | 0.110 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2014 | 21 | 0.110 |
Why?
| | Lyme Disease | 1 | 1995 | 60 | 0.110 |
Why?
| | Calmodulin | 1 | 2014 | 76 | 0.110 |
Why?
| | X Chromosome Inactivation | 2 | 2025 | 25 | 0.110 |
Why?
| | Membrane Proteins | 3 | 2010 | 1164 | 0.110 |
Why?
| | Conotoxins | 1 | 1993 | 14 | 0.110 |
Why?
| | Infant, Newborn | 4 | 2024 | 6079 | 0.110 |
Why?
| | Models, Molecular | 1 | 2019 | 1570 | 0.100 |
Why?
| | Anxiety | 3 | 2022 | 1035 | 0.100 |
Why?
| | Spasm | 2 | 2023 | 20 | 0.100 |
Why?
| | Mental Recall | 3 | 2007 | 202 | 0.100 |
Why?
| | Aged | 13 | 2024 | 23961 | 0.100 |
Why?
| | Demyelinating Diseases | 1 | 1994 | 85 | 0.100 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 35 | 0.100 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 171 | 0.100 |
Why?
| | Angiostrongylus cantonensis | 1 | 2013 | 3 | 0.100 |
Why?
| | Strongylida Infections | 1 | 2013 | 7 | 0.100 |
Why?
| | Vocalization, Animal | 2 | 2024 | 33 | 0.100 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2014 | 156 | 0.100 |
Why?
| | Thiazoles | 1 | 2013 | 123 | 0.100 |
Why?
| | Pregnancy | 3 | 2013 | 6763 | 0.100 |
Why?
| | Functional Laterality | 4 | 2009 | 223 | 0.100 |
Why?
| | Cognition | 1 | 2020 | 1153 | 0.090 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 320 | 0.090 |
Why?
| | Meningitis | 1 | 2013 | 79 | 0.090 |
Why?
| | Down Syndrome | 2 | 2022 | 496 | 0.090 |
Why?
| | Genotype | 3 | 2022 | 1916 | 0.090 |
Why?
| | Dopaminergic Neurons | 1 | 2011 | 69 | 0.090 |
Why?
| | Disks Large Homolog 4 Protein | 2 | 2009 | 18 | 0.090 |
Why?
| | Presynaptic Terminals | 2 | 2009 | 88 | 0.090 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 412 | 0.090 |
Why?
| | Cellular Reprogramming | 1 | 2011 | 99 | 0.090 |
Why?
| | Eosinophilia | 1 | 2013 | 218 | 0.080 |
Why?
| | Leukoencephalopathies | 1 | 2010 | 19 | 0.080 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 840 | 0.080 |
Why?
| | Dominance, Cerebral | 1 | 1989 | 54 | 0.080 |
Why?
| | Guanylate Kinases | 1 | 2009 | 13 | 0.080 |
Why?
| | Cross-Over Studies | 2 | 2025 | 564 | 0.080 |
Why?
| | Pyridines | 1 | 2013 | 506 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 83 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 113 | 0.080 |
Why?
| | Prospective Studies | 5 | 2022 | 7604 | 0.080 |
Why?
| | Mathematical Concepts | 1 | 2009 | 31 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2006 | 1483 | 0.080 |
Why?
| | Language Disorders | 2 | 2007 | 30 | 0.080 |
Why?
| | Prognosis | 3 | 2022 | 4030 | 0.070 |
Why?
| | Reaction Time | 2 | 2009 | 412 | 0.070 |
Why?
| | Receptors, Cholinergic | 1 | 2008 | 37 | 0.070 |
Why?
| | Biomarkers | 3 | 2021 | 4149 | 0.070 |
Why?
| | A Kinase Anchor Proteins | 1 | 2009 | 72 | 0.070 |
Why?
| | Uncertainty | 1 | 2009 | 128 | 0.070 |
Why?
| | Gerbillinae | 3 | 2017 | 65 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2006 | 3556 | 0.070 |
Why?
| | Cells, Cultured | 7 | 2017 | 4193 | 0.070 |
Why?
| | Exploratory Behavior | 1 | 2008 | 92 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2009 | 455 | 0.070 |
Why?
| | Conditioning, Classical | 1 | 2008 | 103 | 0.070 |
Why?
| | Atrophy | 2 | 2001 | 184 | 0.070 |
Why?
| | Cohort Studies | 3 | 2024 | 5742 | 0.070 |
Why?
| | Mossy Fibers, Hippocampal | 1 | 2007 | 11 | 0.070 |
Why?
| | Vertebral Artery Dissection | 1 | 2007 | 24 | 0.070 |
Why?
| | Jejunum | 1 | 2007 | 31 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2007 | 7635 | 0.070 |
Why?
| | Shy-Drager Syndrome | 1 | 2007 | 1 | 0.070 |
Why?
| | Games, Experimental | 1 | 2007 | 11 | 0.070 |
Why?
| | Periodicity | 1 | 2007 | 58 | 0.070 |
Why?
| | Soccer | 1 | 2007 | 42 | 0.070 |
Why?
| | Strontium | 3 | 2017 | 14 | 0.070 |
Why?
| | Glutens | 1 | 2007 | 60 | 0.070 |
Why?
| | Neuromuscular Diseases | 1 | 2008 | 132 | 0.060 |
Why?
| | Antibodies | 1 | 2008 | 410 | 0.060 |
Why?
| | Fibroblasts | 1 | 2011 | 996 | 0.060 |
Why?
| | Football | 1 | 2007 | 85 | 0.060 |
Why?
| | Cross-Linking Reagents | 1 | 2007 | 217 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2007 | 233 | 0.060 |
Why?
| | Bumetanide | 1 | 2005 | 5 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2007 | 523 | 0.060 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2005 | 16 | 0.060 |
Why?
| | Organ of Corti | 1 | 2005 | 14 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2007 | 1738 | 0.060 |
Why?
| | Receptors, Kainic Acid | 1 | 2005 | 10 | 0.060 |
Why?
| | Diuretics | 1 | 2005 | 74 | 0.060 |
Why?
| | Hair Cells, Auditory | 1 | 2005 | 39 | 0.060 |
Why?
| | Auditory Pathways | 1 | 2005 | 52 | 0.060 |
Why?
| | Fear | 1 | 2008 | 338 | 0.060 |
Why?
| | Language | 1 | 2008 | 292 | 0.060 |
Why?
| | Pilot Projects | 2 | 2012 | 1710 | 0.060 |
Why?
| | Communication Disorders | 1 | 2024 | 11 | 0.060 |
Why?
| | Length of Stay | 1 | 2010 | 1215 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 431 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2007 | 547 | 0.060 |
Why?
| | Microcephaly | 1 | 2025 | 98 | 0.060 |
Why?
| | Tomography, Emission-Computed | 1 | 2004 | 66 | 0.060 |
Why?
| | Ion Channel Gating | 1 | 2005 | 90 | 0.060 |
Why?
| | Simplexvirus | 1 | 2004 | 80 | 0.050 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 43 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 100 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2025 | 2057 | 0.050 |
Why?
| | Nerve Net | 1 | 2007 | 256 | 0.050 |
Why?
| | Odorants | 1 | 2024 | 109 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2024 | 183 | 0.050 |
Why?
| | Brain Waves | 1 | 2024 | 33 | 0.050 |
Why?
| | Herpes Simplex | 1 | 2004 | 95 | 0.050 |
Why?
| | Sodium | 1 | 2005 | 217 | 0.050 |
Why?
| | Rare Diseases | 1 | 2024 | 104 | 0.050 |
Why?
| | Failure to Thrive | 1 | 2023 | 29 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2004 | 178 | 0.050 |
Why?
| | Muscle Hypotonia | 1 | 2023 | 33 | 0.050 |
Why?
| | Smell | 1 | 2024 | 117 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2004 | 135 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 786 | 0.050 |
Why?
| | Thirst | 1 | 2003 | 5 | 0.050 |
Why?
| | Stereotypic Movement Disorder | 1 | 2003 | 8 | 0.050 |
Why?
| | Biopsy | 1 | 2007 | 1129 | 0.050 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2023 | 72 | 0.050 |
Why?
| | Vigabatrin | 1 | 2023 | 19 | 0.050 |
Why?
| | Electric Conductivity | 2 | 2004 | 86 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2023 | 3015 | 0.050 |
Why?
| | Third Ventricle | 1 | 2003 | 17 | 0.050 |
Why?
| | Factor Analysis, Statistical | 1 | 2024 | 283 | 0.050 |
Why?
| | Drinking | 1 | 2003 | 42 | 0.050 |
Why?
| | Protein Binding | 3 | 2016 | 2224 | 0.050 |
Why?
| | Longevity | 1 | 2024 | 165 | 0.050 |
Why?
| | Motor Skills | 1 | 2024 | 97 | 0.050 |
Why?
| | Syndactyly | 1 | 2022 | 9 | 0.050 |
Why?
| | Neurons, Afferent | 1 | 2023 | 97 | 0.050 |
Why?
| | Neurologic Examination | 1 | 2003 | 110 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2010 | 1991 | 0.050 |
Why?
| | Aggression | 1 | 2004 | 202 | 0.050 |
Why?
| | Miniature Postsynaptic Potentials | 2 | 2014 | 10 | 0.050 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2023 | 132 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2003 | 245 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5472 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 156 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 623 | 0.050 |
Why?
| | Mammals | 1 | 2023 | 283 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2023 | 205 | 0.040 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.040 |
Why?
| | Anthropometry | 1 | 2022 | 213 | 0.040 |
Why?
| | Comorbidity | 2 | 2022 | 1622 | 0.040 |
Why?
| | Artifacts | 1 | 2001 | 129 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 402 | 0.040 |
Why?
| | Linguistics | 1 | 2000 | 27 | 0.040 |
Why?
| | Cerebral Palsy | 1 | 2022 | 107 | 0.040 |
Why?
| | Motor Skills Disorders | 1 | 2000 | 28 | 0.040 |
Why?
| | Neural Inhibition | 1 | 2001 | 169 | 0.040 |
Why?
| | RNA Interference | 2 | 2014 | 469 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2022 | 363 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 4 | 2004 | 2691 | 0.040 |
Why?
| | Forecasting | 1 | 2001 | 389 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 1 | 2021 | 180 | 0.040 |
Why?
| | Head Injuries, Closed | 1 | 1999 | 48 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 629 | 0.040 |
Why?
| | tau Proteins | 1 | 2020 | 90 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 565 | 0.040 |
Why?
| | Vesicular Transport Proteins | 1 | 1999 | 84 | 0.040 |
Why?
| | Neurology | 1 | 2020 | 113 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2837 | 0.040 |
Why?
| | Cost of Illness | 1 | 2020 | 308 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2021 | 786 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2844 | 0.040 |
Why?
| | Risk Assessment | 1 | 2007 | 3457 | 0.030 |
Why?
| | Chronic Disease | 1 | 2004 | 1793 | 0.030 |
Why?
| | Amyloid beta-Peptides | 1 | 2020 | 220 | 0.030 |
Why?
| | Risk Factors | 3 | 2009 | 10388 | 0.030 |
Why?
| | Family | 1 | 2022 | 671 | 0.030 |
Why?
| | Benzothiadiazines | 1 | 2017 | 3 | 0.030 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 11 | 0.030 |
Why?
| | Nifedipine | 1 | 2017 | 29 | 0.030 |
Why?
| | Emotions | 1 | 2022 | 548 | 0.030 |
Why?
| | Dipeptides | 1 | 2017 | 50 | 0.030 |
Why?
| | Walking | 1 | 2022 | 529 | 0.030 |
Why?
| | Quinoxalines | 1 | 2017 | 66 | 0.030 |
Why?
| | Qualitative Research | 1 | 2024 | 1386 | 0.030 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 1996 | 100 | 0.030 |
Why?
| | Language Tests | 2 | 2007 | 23 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2009 | 80 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 167 | 0.030 |
Why?
| | Models, Biological | 1 | 2023 | 1783 | 0.030 |
Why?
| | Awareness | 1 | 1997 | 103 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2016 | 298 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2005 | 1238 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2018 | 309 | 0.030 |
Why?
| | Neurocognitive Disorders | 1 | 1995 | 26 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2005 | 141 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1999 | 771 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2001 | 455 | 0.030 |
Why?
| | Dendritic Cells | 1 | 1998 | 483 | 0.030 |
Why?
| | Adenoviridae | 1 | 1996 | 193 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2020 | 762 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 1996 | 170 | 0.030 |
Why?
| | Genetic Vectors | 1 | 1996 | 319 | 0.030 |
Why?
| | Electric Stimulation | 2 | 2005 | 264 | 0.030 |
Why?
| | Peptides | 2 | 2016 | 985 | 0.030 |
Why?
| | Mollusk Venoms | 1 | 1993 | 1 | 0.030 |
Why?
| | Ibotenic Acid | 1 | 1993 | 5 | 0.030 |
Why?
| | 2-Amino-5-phosphonovalerate | 1 | 1993 | 10 | 0.030 |
Why?
| | Neural Pathways | 2 | 2005 | 295 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2014 | 269 | 0.030 |
Why?
| | Heart Diseases | 1 | 1997 | 346 | 0.030 |
Why?
| | Pyramidal Tracts | 1 | 1993 | 31 | 0.030 |
Why?
| | Point Mutation | 1 | 2014 | 235 | 0.030 |
Why?
| | DNA, Helminth | 1 | 2013 | 20 | 0.030 |
Why?
| | Magnesium | 1 | 1993 | 156 | 0.030 |
Why?
| | Reading | 1 | 1994 | 135 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2014 | 390 | 0.020 |
Why?
| | Cerebral Infarction | 2 | 1989 | 44 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2009 | 860 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2014 | 810 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2012 | 93 | 0.020 |
Why?
| | Cerebellum | 1 | 1994 | 224 | 0.020 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2011 | 8 | 0.020 |
Why?
| | Transfection | 2 | 2009 | 945 | 0.020 |
Why?
| | Memory, Episodic | 1 | 2012 | 52 | 0.020 |
Why?
| | Aging | 2 | 2021 | 1864 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1993 | 259 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 622 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2012 | 234 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 465 | 0.020 |
Why?
| | Levodopa | 1 | 1991 | 30 | 0.020 |
Why?
| | SOXB1 Transcription Factors | 1 | 2011 | 62 | 0.020 |
Why?
| | Trihexyphenidyl | 1 | 1991 | 1 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2167 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2003 | 2654 | 0.020 |
Why?
| | Aphasia, Wernicke | 1 | 1989 | 2 | 0.020 |
Why?
| | Anomia | 1 | 1989 | 2 | 0.020 |
Why?
| | Aphasia, Broca | 1 | 1989 | 3 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2011 | 243 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1062 | 0.020 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2009 | 82 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 98 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 399 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 470 | 0.020 |
Why?
| | Germ Cells | 1 | 2009 | 64 | 0.020 |
Why?
| | Dopamine | 1 | 2011 | 303 | 0.020 |
Why?
| | Dendritic Spines | 1 | 2009 | 65 | 0.020 |
Why?
| | Calcineurin | 1 | 2009 | 108 | 0.020 |
Why?
| | Austria | 1 | 2008 | 6 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2009 | 179 | 0.020 |
Why?
| | Switzerland | 1 | 2008 | 37 | 0.020 |
Why?
| | Probability | 1 | 2009 | 304 | 0.020 |
Why?
| | Netherlands | 1 | 2008 | 88 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2009 | 307 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2008 | 171 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 518 | 0.020 |
Why?
| | Germany | 1 | 2008 | 121 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2011 | 506 | 0.020 |
Why?
| | Picrotoxin | 1 | 2007 | 12 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 410 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2007 | 35 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 1988 | 108 | 0.020 |
Why?
| | Alcoholism | 1 | 1994 | 807 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1988 | 96 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 861 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 310 | 0.020 |
Why?
| | Brain Mapping | 1 | 1989 | 503 | 0.020 |
Why?
| | Electromyography | 1 | 2008 | 400 | 0.020 |
Why?
| | United States | 1 | 2023 | 14841 | 0.020 |
Why?
| | Solute Carrier Family 12, Member 2 | 1 | 2005 | 7 | 0.020 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2005 | 9 | 0.020 |
Why?
| | Phenobarbital | 1 | 2005 | 19 | 0.020 |
Why?
| | Electric Capacitance | 1 | 2005 | 6 | 0.020 |
Why?
| | Turtles | 1 | 2005 | 11 | 0.020 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2005 | 5 | 0.020 |
Why?
| | Sclerosis | 1 | 2005 | 13 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2005 | 40 | 0.010 |
Why?
| | Head Movements | 1 | 2005 | 19 | 0.010 |
Why?
| | Videotape Recording | 1 | 2005 | 35 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 2005 | 125 | 0.010 |
Why?
| | Synaptic Vesicles | 1 | 2005 | 44 | 0.010 |
Why?
| | Aspartic Acid | 1 | 2005 | 79 | 0.010 |
Why?
| | Cadmium | 1 | 2005 | 69 | 0.010 |
Why?
| | Neural Conduction | 1 | 2005 | 86 | 0.010 |
Why?
| | Basal Ganglia | 1 | 2005 | 56 | 0.010 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2005 | 156 | 0.010 |
Why?
| | Rotation | 1 | 2005 | 117 | 0.010 |
Why?
| | Chelating Agents | 1 | 2005 | 75 | 0.010 |
Why?
| | Monte Carlo Method | 1 | 2005 | 148 | 0.010 |
Why?
| | Video Recording | 1 | 2005 | 180 | 0.010 |
Why?
| | Acyclovir | 1 | 2004 | 101 | 0.010 |
Why?
| | Posture | 1 | 2005 | 185 | 0.010 |
Why?
| | Reference Values | 2 | 1999 | 816 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2011 | 2475 | 0.010 |
Why?
| | Vomiting | 1 | 2004 | 130 | 0.010 |
Why?
| | Drug Interactions | 1 | 2005 | 410 | 0.010 |
Why?
| | Attention | 1 | 2007 | 427 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1719 | 0.010 |
Why?
| | Fever | 1 | 2004 | 306 | 0.010 |
Why?
| | Monitoring, Intraoperative | 1 | 2003 | 56 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2804 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2005 | 332 | 0.010 |
Why?
| | Computer Simulation | 1 | 2005 | 978 | 0.010 |
Why?
| | N-Ethylmaleimide-Sensitive Proteins | 1 | 1999 | 5 | 0.010 |
Why?
| | Prevalence | 1 | 2007 | 2734 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1786 | 0.010 |
Why?
| | Water | 1 | 2003 | 460 | 0.010 |
Why?
| | Colorado | 1 | 2009 | 4565 | 0.010 |
Why?
| | Rats, Wistar | 1 | 1998 | 455 | 0.010 |
Why?
| | Dizocilpine Maleate | 1 | 1996 | 22 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 202 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 1996 | 78 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1353 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1670 | 0.010 |
Why?
| | Cell Survival | 1 | 1996 | 1120 | 0.010 |
Why?
| | Brain Concussion | 1 | 1999 | 574 | 0.010 |
Why?
| | Receptors, Dopamine | 1 | 1991 | 20 | 0.010 |
Why?
| | Intelligence Tests | 1 | 1991 | 57 | 0.010 |
Why?
| | Psychological Tests | 1 | 1991 | 140 | 0.010 |
Why?
| | Frontal Lobe | 1 | 1991 | 149 | 0.010 |
Why?
| | Kidney | 1 | 1996 | 1468 | 0.000 |
Why?
| | Cerebral Ventricles | 1 | 1988 | 52 | 0.000 |
Why?
| | Hypertension | 1 | 1988 | 1295 | 0.000 |
Why?
|
|
Benke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|